Aura Biosciences (AURA) Liabilities and Shareholders Equity (2020 - 2026)

Aura Biosciences has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $137.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 11.41% year-over-year to $137.7 million; the trailing twelve-month figure through Mar 2026 stood at $701.5 million (down 7.88% YoY), and the FY2025 full-year result was $169.4 million, down 7.16% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $137.7 million, down from $169.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $255.1 million in Q4 2023, with the low at $135.0 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $187.1 million across 5 years, with a median of $190.0 million in 2025.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 57.82% — and 2025, when it sank 33.88%.
• Aura Biosciences' Liabilities and Shareholders Equity stood at $223.9 million in 2022, then advanced by 13.91% to $255.1 million in 2023, then dropped by 28.45% to $182.5 million in 2024, then dropped by 7.16% to $169.4 million in 2025, then slipped by 18.74% to $137.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $137.7 million (Q1 2026), $169.4 million (Q4 2025), and $190.0 million (Q3 2025), per Business Quant data.